Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer
Abstract
:1. Introduction
2. Results
2.1. Sdc Family Members and Sdcbp mRNA Levels in GEMM of PCa
2.2. SDC Family and SDCBP Protein Expression in Knockout Mice Prostatic Tissues
2.3. Immunohistochemical Analysis of SDC Family Members and SDCBP in Human Prostate Tissues
2.4. Gleason Score Correlation and Survival Curves
2.5. Prognostic Value by Time of Biochemical Recurrence Analysis Using Gene Expression Patterns in Public Datasets
3. Discussion
4. Materials and Methods
4.1. Gene Expression Analysis of Sdc1-4 and Sdcbp in Two Genetically Engineered Mouse Models (GEMM) of PCa: Pten and p53/Rb Conditional Knockouts
4.2. Immunohistochemistry (IHC) Staining in Mouse Sample Analysis
4.3. Patient Tissue Sample Microarray
4.4. Prognostic Value Analysis in Public Datasets
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
- Lilja, H.; Ulmert, D.; Vickers, A.J. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat. Rev. Cancer 2008, 8, 268–278. [Google Scholar] [CrossRef]
- Choudhury, A.D.; Eeles, R.; Freedland, S.J.; Isaacs, W.B.; Pomerantz, M.M.; Schalken, J.A.; Tammela, T.L.; Visakorpi, T. The role of genetic markers in the management of prostate cancer. Eur. Urol. 2012, 62, 577–587. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y.T.; Delijani, K.; Mecum, A.; Goldkorn, A. Current status of liquid biopsies for the detection and management of prostate cancer. Cancer Manag. Res. 2019, 11, 5271–5291. [Google Scholar] [CrossRef] [Green Version]
- Campos-Fernández, E.; Barcelos, L.S.; de Souza, A.G.; Goulart, L.R.; Alonso-Goulart, V. Research landscape of liquid biopsies in prostate cancer. Am. J. Cancer Res. 2019, 9, 1309–1328. [Google Scholar] [PubMed]
- Iozzo, R.V.; Schaefer, L. Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. Matrix Biol. 2015, 42, 11–55. [Google Scholar] [CrossRef] [PubMed]
- Theocharis, A.D.; Skandalis, S.S.; Neill, T.; Multhaupt, H.A.; Hubo, M.; Frey, H.; Gopal, S.; Gomes, A.; Afratis, N.; Lim, H.C.; et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim. Biophys. Acta 2015, 1855, 276–300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Couchman, J.R. Syndecans: Proteoglycan regulators of cell-surface microdomains? Nat. Rev. Mol. Cell Biol. 2003, 4, 926–937. [Google Scholar] [CrossRef]
- Xian, X.; Gopal, S.; Couchman, J.R. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res. 2010, 339, 31–46. [Google Scholar] [CrossRef]
- Gould, S.E.; Upholt, W.B.; Kosher, R.A. Syndecan 3: A member of the syndecan family of membrane-intercalated proteoglycans that is expressed in high amounts at the onset of chicken limb cartilage differentiation. Proc. Natl. Acad. Sci. USA 1992, 89, 3271–3275. [Google Scholar] [CrossRef] [Green Version]
- Afratis, N.A.; Nikitovic, D.; Multhaupt, H.A.; Theocharis, A.D.; Couchman, J.R.; Karamanos, N.K. Syndecans-key regulators of cell signaling and biological functions. FEBS J. 2017, 284, 27–41. [Google Scholar] [CrossRef] [Green Version]
- Kim, C.W.; Goldberger, O.A.; Gallo, R.L.; Bernfield, M. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol. Biol. Cell 1994, 5, 797–805. [Google Scholar] [CrossRef] [Green Version]
- Szatmári, T.; Ötvös, R.; Hjerpe, A.; Dobra, K. Syndecan-1 in cancer: Implications for cell signaling, differentiation, and prognostication. Dis. Markers 2015, 2015, 796052. [Google Scholar] [CrossRef] [Green Version]
- Baietti, M.F.; Zhang, Z.; Mortier, E.; Melchior, A.; Degeest, G.; Geeraerts, A.; Ivarsson, Y.; Depoortere, F.; Coomans, C.; Vermeiren, E.; et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 2012, 14, 677–685. [Google Scholar] [CrossRef] [PubMed]
- Roucourt, B.; Meeussen, S.; Bao, J.; Zimmermann, P.; David, G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res. 2015, 25, 412–428. [Google Scholar] [CrossRef] [Green Version]
- Cheng, B.; Montmasson, M.; Terradot, L.; Rousselle, P. Syndecans as cell surface receptors in cancer biology. a focus on their interaction with pdz domain proteins. Front. Pharmacol. 2016, 7, 10. [Google Scholar] [CrossRef] [Green Version]
- Couchman, J.R.; Gopal, S.; Lim, H.C.; Norgaard, S.; Multhaupt, H.A. Fell-Muir lecture: Syndecans: From peripheral coreceptors to mainstream regulators of cell behaviour. Int. J. Exp. Pathol. 2015, 96, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Couchman, J.R. Syndecan-1 (CD138), Carcinomas and EMT. Int. J. Mol. Sci. 2021, 22, 4227. [Google Scholar] [CrossRef]
- Czarnowski, D. Syndecans in cancer: A review of function, expression, prognostic value, and therapeutic significance. Cancer Treat. Res. Commun. 2021, 27, 100312. [Google Scholar] [CrossRef] [PubMed]
- Gondelaud, F.; Ricard-Blum, S. Structures and interactions of syndecans. FEBS J. 2019, 286, 2994–3007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meng, F.; Han, X.; Min, Z.; He, X.; Zhu, S. Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer. Aging 2021, 13, 17442–17461. [Google Scholar] [CrossRef]
- Kang, H.; Wu, Q.; Sun, A.; Liu, X.; Fan, Y.; Deng, X. Cancer cell glycocalyx and its significance in cancer progression. Int. J. Mol. Sci. 2018, 19, 2484. [Google Scholar] [CrossRef] [Green Version]
- Loftus, P.G.; Watson, L.; Deedigan, L.M.; Camarillo-Retamosa, E.; Dwyer, R.M.; O’Flynn, L.; Alagesan, S.; Griffin, M.; O’Brien, T.; Kerin, M.J.; et al. Targeting stromal cell Syndecan-2 reduces breast tumour growth, metastasis and limits immune evasion. Int. J. Cancer 2021, 148, 1245–1259. [Google Scholar] [CrossRef]
- Fujii, T.; Shimada, K.; Tatsumi, Y.; Tanaka, N.; Fujimoto, K.; Konishi, N. Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer. Mol. Carcinog. 2016, 55, 1378–1386. [Google Scholar] [CrossRef] [PubMed]
- Edwards, I.J. Proteoglycans in prostate cancer. Nat. Rev. Urol. 2012, 9, 196–206. [Google Scholar] [CrossRef] [PubMed]
- Stepp, M.A.; Pal-Ghosh, S.; Tadvalkar, G.; Rajjoub, L.; Jurjus, R.A.; Gerdes, M.; Ryscavage, A.; Cataisson, C.; Shukla, A.; Yuspa, S.H. Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis. Mol. Carcinog. 2010, 49, 363–373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Parimon, T.; Brauer, R.; Schlesinger, S.Y.; Xie, T.; Jiang, D.; Ge, L.; Huang, Y.; Birkland, T.P.; Parks, W.C.; Habiel, D.M.; et al. Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes. Am. J. Pathol. 2018, 188, 1094–1103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wei, H.T.; Guo, E.N.; Dong, B.G.; Chen, L.S. Prognostic and clinical significance of syndecan-1 in colorectal cancer: A meta-analysis. BMC Gastroenterol. 2015, 15, 152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palaiologou, M.; Delladetsima, I.; Tiniakos, D. CD138 (syndecan-1) expression in health and disease. Histol. Histopathol. 2014, 29, 177–189. [Google Scholar] [CrossRef]
- Das, S.K.; Sarkar, D.; Emdad, L.; Fisher, P.B. MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis. Adv. Cancer Res. 2019, 144, 137–191. [Google Scholar] [CrossRef]
- Pradhan, A.K.; Maji, S.; Das, S.K.; Emdad, L.; Sarkar, D.; Fisher, P.B. MDA-9/Syntenin/SDCBP: New insights into a unique multifunctional scaffold protein. Cancer Metastasis Rev. 2020, 39, 769–781. [Google Scholar] [CrossRef]
- Sharpe, B.; Alghezi, D.A.; Cattermole, C.; Beresford, M.; Bowen, R.; Mitchard, J.; Chalmers, A.D. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells. Prostate 2017, 77, 1312–1324. [Google Scholar] [CrossRef] [PubMed]
- Szarvas, T.; Sevcenco, S.; Modos, O.; Keresztes, D.; Nyirady, P.; Kubik, A.; Romics, M.; Kovalszky, I.; Reis, H.; Hadaschik, B.; et al. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. Urol. Oncol. 2018, 36, 312.e9–312.e15. [Google Scholar] [CrossRef]
- Chen, D.; Adenekan, B.; Chen, L.; Vaughan, E.D.; Gerald, W.; Feng, Z.; Knudsen, B.S. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004, 63, 402–407. [Google Scholar] [CrossRef]
- Kiviniemi, J.; Kallajoki, M.; Kujala, I.; Matikainen, M.T.; Alanen, K.; Jalkanen, M.; Salmivirta, M. Altered expression of syndecan-1 in prostate cancer. APMIS 2004, 112, 89–97. [Google Scholar] [CrossRef] [PubMed]
- Popovic, A.; Demirovic, A.; Spajic, B.; Stimac, G.; Kruslin, B.; Tomas, D. Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis. 2010, 13, 78–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dunning, M.J.; Vowler, S.L.; Lalonde, E.; Ross-Adams, H.; Boutros, P.; Mills, I.G.; Lynch, A.G.; Lamb, A.D. Mining human prostate cancer datasets: The camcAPP shiny app. eBioMedicine 2017, 17, 5–6. [Google Scholar] [CrossRef] [Green Version]
- Ross-Adams, H.; Lamb, A.D.; Dunning, M.J.; Halim, S.; Lindberg, J.; Massie, C.M.; Egevad, L.A.; Russell, R.; Ramos-Montoya, A.; Vowler, S.L.; et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. eBioMedicine 2015, 2, 1133–1144. [Google Scholar] [CrossRef] [Green Version]
- Taylor, B.S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B.S.; Arora, V.K.; Kaushik, P.; Cerami, E.; Reva, B.; et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18, 11–22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aguirre-Gamboa, R.; Gomez-Rueda, H.; Martinez-Ledesma, E.; Martinez-Torteya, A.; Chacolla-Huaringa, R.; Rodriguez-Barrientos, A.; Tamez-Pena, J.G.; Trevino, V. SurvExpress: An online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 2013, 8, e74250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401–404. [Google Scholar] [CrossRef] [Green Version]
- Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, pl1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abida, W.; Cyrta, J.; Heller, G.; Prandi, D.; Armenia, J.; Coleman, I.; Cieslik, M.; Benelli, M.; Robinson, D.; Van Allen, E.M.; et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 2019, 116, 11428–11436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Soares, M.A.; Teixeira, F.C.; Fontes, M.; Areas, A.L.; Leal, M.G.; Pavao, M.S.; Stelling, M.P. Heparan sulfate proteoglycans may promote or inhibit cancer progression by interacting with integrins and affecting cell migration. Biomed. Res. Int. 2015, 2015, 453801. [Google Scholar] [CrossRef] [Green Version]
- Suhovskih, A.V.; Aidagulova, S.V.; Kashuba, V.I.; Grigorieva, E.V. Proteoglycans as potential microenvironmental biomarkers for colon cancer. Cell Tissue Res. 2015, 361, 833–844. [Google Scholar] [CrossRef]
- Okolicsanyi, R.K.; Buffiere, A.; Jacinto, J.M.; Chacon-Cortes, D.; Chambers, S.K.; Youl, P.H.; Haupt, L.M.; Griffiths, L.R. Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms with breast cancer in an Australian Caucasian population. Tumour Biol. 2015, 36, 1731–1738. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suhovskih, A.V.; Mostovich, L.A.; Kunin, I.S.; Boboev, M.M.; Nepomnyashchikh, G.I.; Aidagulova, S.V.; Grigorieva, E.V. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol. 2013, 2013, 680136. [Google Scholar] [CrossRef] [PubMed]
- Brimo, F.; Vollmer, R.T.; Friszt, M.; Corcos, J.; Bismar, T.A. Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression. BJU Int. 2010, 106, 418–423. [Google Scholar] [CrossRef]
- Shimada, K.; Anai, S.; Fujii, T.; Tanaka, N.; Fujimoto, K.; Konishi, N. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. J. Pathol. 2013, 231, 495–504. [Google Scholar] [CrossRef]
- Zellweger, T.; Ninck, C.; Mirlacher, M.; Annefeld, M.; Glass, A.G.; Gasser, T.C.; Mihatsch, M.J.; Gelmann, E.P.; Bubendorf, L. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003, 55, 20–29. [Google Scholar] [CrossRef] [PubMed]
- Ledezma, R.; Cifuentes, F.; Gallegos, I.; Fulla, J.; Ossandon, E.; Castellon, E.A.; Contreras, H.R. Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer. Asian J. Androl. 2011, 13, 476–480. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, Z.; Flesken-Nikitin, A.; Corney, D.C.; Wang, W.; Goodrich, D.W.; Roy-Burman, P.; Nikitin, A.Y. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 2006, 66, 7889–7898. [Google Scholar] [CrossRef] [Green Version]
- Jurmeister, S.; Ramos-Montoya, A.; Sandi, C.; Pertega-Gomes, N.; Wadhwa, K.; Lamb, A.D.; Dunning, M.J.; Attig, J.; Carroll, J.S.; Fryer, L.G.; et al. Identification of potential therapeutic targets in prostate cancer through a cross-species approach. EMBO Mol. Med. 2018. [Google Scholar] [CrossRef]
- Diamantopoulou, Z.; Kitsou, P.; Menashi, S.; Courty, J.; Katsoris, P. Loss of receptor protein tyrosine phosphatase beta/zeta (RPTPbeta/zeta) promotes prostate cancer metastasis. J. Biol. Chem. 2012, 287, 40339–40349. [Google Scholar] [CrossRef] [Green Version]
- Yao, J.; Zhang, L.L.; Huang, X.M.; Li, W.Y.; Gao, S.G. Pleiotrophin and N-syndecan promote perineural invasion and tumor progression in an orthotopic mouse model of pancreatic cancer. World J. Gastroenterol. 2017, 23, 3907–3914. [Google Scholar] [CrossRef] [PubMed]
- Yao, J.; Li, W.Y.; Li, S.G.; Feng, X.S.; Gao, S.G. Midkine promotes perineural invasion in human pancreatic cancer. World J. Gastroenterol. 2014, 20, 3018–3024. [Google Scholar] [CrossRef] [PubMed]
- Labropoulou, V.T.; Skandalis, S.S.; Ravazoula, P.; Perimenis, P.; Karamanos, N.K.; Kalofonos, H.P.; Theocharis, A.D. Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours. Biomed. Res. Int. 2013, 2013, 214864. [Google Scholar] [CrossRef] [PubMed]
- Friand, V.; David, G.; Zimmermann, P. Syntenin and syndecan in the biogenesis of exosomes. Biol. Cell 2015, 107, 331–341. [Google Scholar] [CrossRef]
- Chiasserini, D.; Mazzoni, M.; Bordi, F.; Sennato, S.; Susta, F.; Orvietani, P.L.; Binaglia, L.; Palmerini, C.A. Identification and partial characterization of two populations of prostasomes by a combination of dynamic light scattering and proteomic analysis. J. Membr. Biol. 2015. [Google Scholar] [CrossRef]
- Das, S.K.; Pradhan, A.K.; Bhoopathi, P.; Talukdar, S.; Shen, X.N.; Sarkar, D.; Emdad, L.; Fisher, P.B. The MDA-9/Syntenin/IGF1R/STAT3 axis directs prostate cancer invasion. Cancer Res. 2018, 78, 2852–2863. [Google Scholar] [CrossRef] [Green Version]
- Talukdar, S.; Das, S.K.; Pradhan, A.K.; Emdad, L.; Windle, J.J.; Sarkar, D.; Fisher, P.B. MDA-9/Syntenin (SDCBP) is a critical regulator of chemoresistance, survival and stemness in prostate cancer stem cells. Cancers 2019, 12, 53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Das, S.K.; Kegelman, T.P.; Pradhan, A.K.; Shen, X.N.; Bhoopathi, P.; Talukdar, S.; Maji, S.; Sarkar, D.; Emdad, L.; Fisher, P.B. Suppression of prostate cancer pathogenesis using an MDA-9/Syntenin (SDCBP) PDZ1 small-molecule inhibitor. Mol. Cancer Ther. 2019, 18, 1997–2007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qian, B.; Yao, Z.; Yang, Y.; Li, N.; Wang, Q. Downregulation of SDCBP inhibits cell proliferation and induces apoptosis by regulating PI3K/AKT/mTOR pathway in gastric carcinoma. Biotechnol. Appl. Biochem. 2021, in press. [Google Scholar] [CrossRef]
- Wang, S.; Gao, J.; Lei, Q.; Rozengurt, N.; Pritchard, C.; Jiao, J.; Thomas, G.V.; Li, G.; Roy-Burman, P.; Nelson, P.S.; et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4, 209–221. [Google Scholar] [CrossRef] [Green Version]
- Svensson, R.U.; Haverkamp, J.M.; Thedens, D.R.; Cohen, M.B.; Ratliff, T.L.; Henry, M.D. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am. J. Pathol. 2011, 179, 502–512. [Google Scholar] [CrossRef]
- Jamaspishvili, T.; Berman, D.M.; Ross, A.E.; Scher, H.I.; De Marzo, A.M.; Squire, J.A.; Lotan, T.L. Clinical implications of PTEN loss in prostate cancer. Nat. Rev. Urol. 2018, 15, 222–234. [Google Scholar] [CrossRef] [PubMed]
- Barquilha, C.N.; Santos, N.J.; Monção, C.C.D.; Barbosa, I.C.; Lima, F.O.; Justulin, L.A.; Pértega-Gomes, N.; Felisbino, S.L. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer. Oxid Med. Cell Longev. 2020, 2020, 2148562. [Google Scholar] [CrossRef]
- Abeshouse, A. The molecular taxonomy of primary prostate cancer. Cell 2015, 163, 1011–1025. [Google Scholar] [CrossRef] [Green Version]
- Fedor, H.L.; De Marzo, A.M. Practical methods for tissue microarray construction. Methods Mol. Med. 2005, 103, 89–101. [Google Scholar]
- Fowler, C.B.; Man, Y.G.; Zhang, S.; O’Leary, T.J.; Mason, J.T.; Cunningham, R.E. Tissue microarrays: Construction and uses. Methods Mol. Biol. 2011, 724, 23–35. [Google Scholar] [CrossRef] [PubMed]
Protein | Gleason Score | Chi-Square p-Value | |||
---|---|---|---|---|---|
<7 (n = 46–50) | =7 (n = 18–19) | >7 (n = 36–37) | Percentage (%) | ||
SDC1 | |||||
Positive | 34 | 14 | 29 | 72.64 | 0.5585 |
Negative | 16 | 5 | 8 | 27.36 | |
SDC2 | |||||
Positive | 23 | 12 | 23 | 55.24 | 0.2774 |
Negative | 26 | 7 | 14 | 44.76 | |
SDC3 | |||||
Positive | 9 | 6 | 19 | 32.38 | 0.0053 |
Negative | 40 | 13 | 18 | 67.62 | |
SDC4 | |||||
Positive | 27 | 13 | 29 | 68.32 | 0.1076 |
Negative | 19 | 6 | 7 | 31.68 | |
SDCBP | |||||
Positive | 40 | 14 | 29 | 81.37 | 0.8646 |
Negative | 8 | 4 | 7 | 18.63 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Santos, N.J.; Barquilha, C.N.; Barbosa, I.C.; Macedo, R.T.; Lima, F.O.; Justulin, L.A.; Barbosa, G.O.; Carvalho, H.F.; Felisbino, S.L. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer. Int. J. Mol. Sci. 2021, 22, 8669. https://doi.org/10.3390/ijms22168669
Santos NJ, Barquilha CN, Barbosa IC, Macedo RT, Lima FO, Justulin LA, Barbosa GO, Carvalho HF, Felisbino SL. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer. International Journal of Molecular Sciences. 2021; 22(16):8669. https://doi.org/10.3390/ijms22168669
Chicago/Turabian StyleSantos, Nilton José, Caroline Nascimento Barquilha, Isabela Correa Barbosa, Rodrigo Tavares Macedo, Flávio Oliveira Lima, Luis Antônio Justulin, Guilherme Oliveira Barbosa, Hernandes F. Carvalho, and Sérgio Luis Felisbino. 2021. "Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer" International Journal of Molecular Sciences 22, no. 16: 8669. https://doi.org/10.3390/ijms22168669